DUAL INHIBITION OF CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE AND mTOR AS A NEW THERAPEUTIC OPTION FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

類似資料

• Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels
  著者:: Bressanin, Daniela, 等
  出版事項: (2012)
• Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
  著者:: Camilla Evangelisti, 等
  出版事項: (2018-06-01)
• Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
  著者:: Evangelisti, Camilla, 等
  出版事項: (2018)
• A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
  著者:: Chiarini, Francesca, 等
  出版事項: (2012)
• The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
  著者:: Martelli, Alberto M., 等
  出版事項: (2010)